survivin mRNA antagonist EZN-3042

A locked nucleic acid (LNA) antisense oligonucleotide targeting survivin mRNA, with potential antineoplastic activity. EZN-3042 hybridizes to survivin mRNA, thereby blocking translation of survivin protein and inhibiting survivin-induced anti-apoptotic activity and promoting tumor cell apoptosis in survivin-overexpressing tumor cells. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy. LNAs contain a methylene bridge linking 2′-oxygen and 4′-carbon of ribose sugar rings, thereby increasing their stability and decreasing degradation. Check for active clinical trials using this agent. (NCI Thesaurus)

Related Posts

Award Winning Physicians

Our Physicians work for you, ensuring the highest standard of care.

Learn More